{"product_id":"global-viral-vector-partnering-terms-and-agreements-2016-to-2023","title":"Global Viral Vector Partnering Terms and Agreements 2016 to 2023","description":"\u003cp\u003eGlobal Viral Vector Partnering Terms and Agreements 2016 to 2023\u003cbr\u003e\nGlobal Viral Vector Partnering Terms and Agreements 2016 to 2023\u003c\/p\u003e\n\n\u003cp\u003eThe Global Viral Vector Partnering Terms and Agreements 2010-2023 report provides comprehensive understanding and unprecedented access to the viral vector partnering deals and agreements entered into by the worlds leading healthcare companies.\u003c\/p\u003e\n\n\u003cp\u003eTrends in viral vector partnering including collaboration and licensing deals\u003cbr\u003e\nPartnering agreement structure\u003cbr\u003e\nPartnering contract documents\u003cbr\u003e\nTop deals by value\u003cbr\u003e\nMost active dealmakers\u003cbr\u003e\nAverage deal terms for viral vectors\u003c\/p\u003e\n\n\u003cp\u003eThe report provides a detailed understanding and analysis of how and why companies enter viral vector partnering deals. These deals tend to be multicomponent, starting with collaborative R\u0026amp;D, and proceed to commercialization of viral vector outcomes\u003c\/p\u003e\n\n\u003cp\u003eThis report provides details of the latest viral vector agreements announced in the life sciences since 2016.\u003c\/p\u003e\n\n\u003cp\u003eThe report takes the reader through a comprehensive review viral vector deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering viral vector partnering deals.\u003c\/p\u003e\n\n\u003cp\u003eThe report presents financial deal term values for viral vector deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.\u003c\/p\u003e\n\n\u003cp\u003eThe middle section of the report explores the leading dealmakers in the viral vector partnering field; both the leading deal values and most active viral vector dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.\u003c\/p\u003e\n\n\u003cp\u003eOne of the key highlights of the report is that over 400 online deal records of actual viral vector deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.\u003c\/p\u003e\n\n\u003cp\u003eIn addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.\u003c\/p\u003e\n\n\u003cp\u003eThe initial chapters of this report provide an orientation of viral vector dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in viral vector dealmaking since 2016, including details of headline, upfront, milestone and royalty terms.\u003c\/p\u003e\n\n\u003cp\u003eChapter 3 provides a review of the leading viral vector deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.\u003c\/p\u003e\n\n\u003cp\u003eChapter 4 provides a comprehensive listing of the top 25 most active companies in viral vector dealmaking with a brief summary followed by a comprehensive listing of viral vector deals announded by that company, as well as contract documents, where available.\u003c\/p\u003e\n\n\u003cp\u003eChapter 5 provides a comprehensive and detailed review of viral vector partnering deals signed and announced since Jan 2016, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.\u003c\/p\u003e\n\n\u003cp\u003eChapter 6 provides a comprehensive and detailed review of viral vector partnering deals signed and announced since Jan 2016. The chapter is organized by specific viral vector technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.\u003c\/p\u003e\n\n\u003cp\u003eA comprehensive series of appendices is provided organized by viral vector partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.\u003c\/p\u003e\n\n\u003cp\u003eThe report also includes numerous tables and figures that illustrate the trends and activities in viral vector partnering and dealmaking since 2016.\u003c\/p\u003e\n\n\u003cp\u003eIn conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of viral vector technologies and products.\u003c\/p\u003e\n\n\u003cp\u003eKey benefits\u003c\/p\u003e\n\n\u003cp\u003eGlobal Viral Vector Partnering Terms and Agreements 2016-2023 provides the reader with the following key benefits:\u003c\/p\u003e\n\n\u003cp\u003eIn-depth understanding of viral vector deal trends since 2016\u003cbr\u003e\nAccess to headline, upfront, milestone and royalty data\u003cbr\u003e\nDetailed access to actual viral vector contracts entered into by leading biopharma companies\u003cbr\u003e\nIdentify most active viral vector dealmakers since 2016\u003cbr\u003e\nInsight into terms included in a viral vector partnering agreement, with real world examples\u003cbr\u003e\nUnderstand the key deal terms companies have agreed in previous deals\u003cbr\u003e\nUndertake due diligence to assess suitability of your proposed deal terms for partner companies\u003c\/p\u003e\n\n\u003cp\u003eReport scope\u003c\/p\u003e\n\n\u003cp\u003eGlobal Viral Vector Partnering Terms and Agreements 2016-2023 is intended to provide the reader with an in-depth understanding and access to viral vector trends and structure of deals entered into by leading companies worldwide.\u003c\/p\u003e\n\n\u003cp\u003eViral Vector Partnering Terms and Agreements includes:\u003c\/p\u003e\n\n\u003cp\u003eTrends in viral vector dealmaking in the biopharma industry since 2016\u003cbr\u003e\nAccess to headline, upfront, milestone and royalty data\u003cbr\u003e\nAccess to viral vector contract documents\u003cbr\u003e\nLeading viral vector deals by value since 2016\u003cbr\u003e\nMost active viral vector dealmakers since 2016\u003c\/p\u003e\n\n\u003cp\u003eIn Global Viral Vector Partnering Terms and Agreements 2016-2023, the available deals are listed by:\u003c\/p\u003e\n\n\u003cp\u003eCompany A-Z\u003cbr\u003e\nHeadline value\u003cbr\u003e\nStage of development at signing\u003cbr\u003e\nDeal component type\u003cbr\u003e\nSpecific therapy target\u003cbr\u003e\nTechnology type\u003c\/p\u003e\n\n\u003cp\u003eEach deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\u003c\/p\u003e\n\n\u003cp\u003eThe Global Viral Vector Partnering Terms and Agreements 2016-2023 report provides comprehensive access to available deals and contract documents for over 400 viral vector deals.\u003c\/p\u003e\n\n\u003cp\u003eAnalyzing actual contract agreements allows assessment of the following:\u003cbr\u003e\nWhat are the precise rights granted or optioned?\u003cbr\u003e\nWhat is actually granted by the agreement to the partner company?\u003cbr\u003e\nWhat exclusivity is granted?\u003cbr\u003e\nWhat is the payment structure for the deal?\u003cbr\u003e\nHow are sales and payments audited?\u003cbr\u003e\nWhat is the deal term?\u003cbr\u003e\nHow are the key terms of the agreement defined?\u003cbr\u003e\nHow are IPRs handled and owned?\u003cbr\u003e\nWho is responsible for commercialization?\u003cbr\u003e\nWho is responsible for development, supply, and manufacture?\u003cbr\u003e\nHow is confidentiality and publication managed?\u003cbr\u003e\nHow are disputes to be resolved?\u003cbr\u003e\nUnder what conditions can the deal be terminated?\u003cbr\u003e\nWhat happens when there is a change of ownership?\u003cbr\u003e\nWhat sublicensing and subcontracting provisions have been agreed?\u003cbr\u003e\nWhich boilerplate clauses does the company insist upon?\u003cbr\u003e\nWhich boilerplate clauses appear to differ from partner to partner or deal type to deal type?\u003cbr\u003e\nWhich jurisdiction does the company insist upon for agreement law?\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"July, 2023 \/ 300 Pages \/ MCW16230947","offer_id":47647236030770,"sku":null,"price":3594.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-viral-vector-partnering-terms-and-agreements-2016-to-2023","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}